Fast-track your healthtech startup’s path to pharma success
The DayOne Accelerator is a 3-month hybrid program designed to support international, high potential, early-stage ventures at the intersection of healthtech with pharma R&D, to refine their value proposition, connect with key industry players, and accelerate their growth. It is based in Basel, Switzerland, Europe’s leading life science innovation hub.
Why you should apply
- Gain unparalleled access to pharma industry experts and key players in the Basel Area
- Develop or refine your pharma-specific value proposition with hands-on mentorship
- Tap into Basel’s world-class life sciences ecosystem – home to global pharma leaders
- Stay independent – our accelerator is equity-free and fee-free
Who is the program for?
- Digital health, medtech and techbio ventures with solutions for pharma R&D
- Pre-Seed to Series A stage, with less than $10M of dilutive funds raised to date
- Startups aiming to collaborate or partner with pharma companies
Ready to scale your healthtech startup?
Application deadline: May 15, 2025
What makes the DayOne Accelerator different?
The DayOne Accelerator is a pharma-readiness program designed for real-world impact:
- No equity, no fees: Keep full ownership of your company
- Pharma-neutral: Agnostic program ensuring input from and access to all major pharma players in the region
- Top-tier mentors & experts: Learn from pharma leaders, investors and entrepreneurs
- Hands-on support: Go beyond theory with practical guidance tailored to your needs
- Industry integration: Unique in-person networking opportunities
Why the Basel Area?
- The Basel Area: Europe’s leading life sciences innovation hub
- Home to industry giants like Novartis, Roche and Lonza
- A thriving startup ecosystem with access to top-tier investors and corporate partners
- Direct connections to pharma innovation hubs in Switzerland and beyond
- The best place for healthtech startups to launch and scale
Discover more about DayOne Accelerator:
DayOne Accelerator accelerates high-potential, early-stage ventures at the intersection of healthtech with the life science industry.
